Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren: Highlights des ASCO-Kongresses 2015

A Gliese; C-J Busch; R Knecht

doi:10.1007/s00106-015-0053-2

Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren

Standard

Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren : Highlights des ASCO-Kongresses 2015. / Gliese, A; Busch, C-J; Knecht, R.

In: HNO, Vol. 63, No. 9, 09.2015, p. 606-11.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gliese, A, Busch, C-J & Knecht, R 2015, 'Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren: Highlights des ASCO-Kongresses 2015', HNO, vol. 63, no. 9, pp. 606-11. https://doi.org/10.1007/s00106-015-0053-2

APA

Gliese, A., Busch, C-J., & Knecht, R. (2015). Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren: Highlights des ASCO-Kongresses 2015. HNO, 63(9), 606-11. https://doi.org/10.1007/s00106-015-0053-2

Vancouver

Gliese A, Busch C-J, Knecht R. Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren: Highlights des ASCO-Kongresses 2015. HNO. 2015 Sep;63(9):606-11. https://doi.org/10.1007/s00106-015-0053-2

Bibtex

@article{0810aaf0386345629f149b013fd4b6dc,

title = "Die wichtigsten Studienergebnisse zur nichtchirurgischen Prim{\"a}rtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren: Highlights des ASCO-Kongresses 2015",

abstract = "At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015, results of current trials dealing with nonsurgical primary treatment of locally advanced head and neck cancer were presented. Regarding concomitant chemoradiotherapy (CRT), studies focused on the dosage and sequence of cisplatin administration are currently particularly featured. Amongst these, a study on dosage reduction in human papilloma virus (HPV)-positive patients was presented. Other investigations addressed substances as alternatives for cisplatin, particularly carboplatin and targeted therapeutic agents. The comparison of concomitant and sequential CRT (induction chemotherapy (ICT) prior to CRT) is still one of the main topics. In addition, studies modifying the ICT regimen or combining subsequent radiotherapy (RT) with the epidermal growth factor receptor (EGFR) antibody cetuximab were presented. A selection of the most important trials are summarized in this article. ",

keywords = "Antibodies, Monoclonal, Carboplatin, Chemoradiotherapy, Cisplatin, Drug Administration Schedule, Head and Neck Neoplasms, Humans, Molecular Targeted Therapy, Neoplasm Invasiveness, Otorhinolaryngologic Surgical Procedures, Treatment Outcome, Congresses, English Abstract",

author = "A Gliese and C-J Busch and R Knecht",

year = "2015",

month = sep,

doi = "10.1007/s00106-015-0053-2",

language = "Deutsch",

volume = "63",

pages = "606--11",

journal = "HNO",

issn = "0017-6192",

publisher = "Springer",

number = "9",

}

RIS

TY - JOUR

T1 - Die wichtigsten Studienergebnisse zur nichtchirurgischen Primärtherapie lokal fortgeschrittener Kopf‑Hals‑Tumoren

T2 - Highlights des ASCO-Kongresses 2015

AU - Gliese, A

AU - Busch, C-J

AU - Knecht, R

PY - 2015/9

Y1 - 2015/9

N2 - At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015, results of current trials dealing with nonsurgical primary treatment of locally advanced head and neck cancer were presented. Regarding concomitant chemoradiotherapy (CRT), studies focused on the dosage and sequence of cisplatin administration are currently particularly featured. Amongst these, a study on dosage reduction in human papilloma virus (HPV)-positive patients was presented. Other investigations addressed substances as alternatives for cisplatin, particularly carboplatin and targeted therapeutic agents. The comparison of concomitant and sequential CRT (induction chemotherapy (ICT) prior to CRT) is still one of the main topics. In addition, studies modifying the ICT regimen or combining subsequent radiotherapy (RT) with the epidermal growth factor receptor (EGFR) antibody cetuximab were presented. A selection of the most important trials are summarized in this article.

AB - At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015, results of current trials dealing with nonsurgical primary treatment of locally advanced head and neck cancer were presented. Regarding concomitant chemoradiotherapy (CRT), studies focused on the dosage and sequence of cisplatin administration are currently particularly featured. Amongst these, a study on dosage reduction in human papilloma virus (HPV)-positive patients was presented. Other investigations addressed substances as alternatives for cisplatin, particularly carboplatin and targeted therapeutic agents. The comparison of concomitant and sequential CRT (induction chemotherapy (ICT) prior to CRT) is still one of the main topics. In addition, studies modifying the ICT regimen or combining subsequent radiotherapy (RT) with the epidermal growth factor receptor (EGFR) antibody cetuximab were presented. A selection of the most important trials are summarized in this article.

KW - Antibodies, Monoclonal

KW - Carboplatin

KW - Chemoradiotherapy

KW - Cisplatin

KW - Drug Administration Schedule

KW - Head and Neck Neoplasms

KW - Humans

KW - Molecular Targeted Therapy

KW - Neoplasm Invasiveness

KW - Otorhinolaryngologic Surgical Procedures

KW - Treatment Outcome

KW - Congresses

KW - English Abstract

U2 - 10.1007/s00106-015-0053-2

DO - 10.1007/s00106-015-0053-2

M3 - SCORING: Zeitschriftenaufsatz

C2 - 26303521

VL - 63

SP - 606

EP - 611

JO - HNO

JF - HNO

SN - 0017-6192

IS - 9

ER -